ARCHIVES

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Limb-Sparing Surgery May Not Offer Better Quality of Life

August 28, 2009

New Control Grant Guidelines Include Community Resources Development

August 22, 1975

The Walgreens Connection: ACS Calls On Drug Stores To Stop Tobacco Sales

April 18, 2014

Waxman Subcommittee Hears Support For Cancer Act Renewal

March 7, 1980

Clinical Trials Approved By NCI CTEP Last Month

March 25, 2011

House Panel Recommends $642 Million Increase For NIH; $31 Million Increase For NCI

July 21, 1995